R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

The interconnected web of antimicrobial resistance

One world, one health: The interconnected web of antimicrobi...

Tackling antimicrobial resistance (AMR) requires a one health approach that joins the dots between the human, animal, and environmental drivers, consequences, and data.

R&D

Janssen on driving R&D innovation with data science

The amount of patient data has skyrocketed, providing opportunities to gain a deeper understanding of diseases that are particularly complex or areas with a high level of unmet need, accord

R&D

Early diagnosis key to future Alzheimer’s treatments

The approval of Biogen’s Alzheimer’s treatment could herald a new generation of therapies, but before that can happen, more investment and better diagnostics may be needed, explains Ben Har

R&D

The transformation of brain implants

Nicolas Vachicouras, CEO of Neurosoft Bioelectronics, tells us how Neurosoft's electrode implant aims to reduce inflammation and scar tissue for patients, provide higher quality brain recor

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

The power of R&D collaborations to improve outcomes in rare ...

Far more common than initially thought, rare disease treatments remain far too scarce.

R&D

Novartis’ Amit Nastik on COVID’s supply chain impact: the ph...

Episode 41 of the pharmaphorum podcast heard from Amit Nastik about the impact of COVID-19 on pharma supply chains and how he and his team mitigated disruption to Novartis’ own operations.<